Opdivo-Cabometyx shows long-term effects in primary care of kidney cancer

Media coverage

• Title	Opdivo-Cabometyx shows long-term effects in primary care of kidney cancer
  Media name/outlet	Korea Biomedical Review
  Date	15/02/23
  URL	ct.moreover.com/?a=50012704138&p=1gw&v=1&x=7MbnLt64wR_VUbJ_er3-_A
  Persons	Mauricio Burotto

• Title	Pharma Opdivo-Cabometyx shows long-term effects in primary care of kidney cancer The combination therapy of Opdivo (nivolumab), immunotherapy of BMS and Ono Pharmaceutical, and Ipsen’s targeted agent Cabometyx (cabozantinib) has demonstrated long-term eff
  Media name/outlet	Korea Biomedical Review
  Date	15/02/23
  URL	ct.moreover.com/?a=50013842525&p=1gw&v=1&x=QXFSWNuhlknLiaiDev145Q
  Persons	Mauricio Burotto